Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT06657053

Risk Factors of Epistaxis Recurrence in Adults

We study all patients admitted to the Emergency Department in the Institution between 01/2022 and 07/2023. The information about the recurrence of nose bleeding was searched on their medical file and by calling the patient to confirm ou get the information. Thus, several potentiel risk factors were studied.

The relation between recurrence and those factors were studied at first individually and then all the significant ones were analyzed with a multivarious statistical test.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

About this study

We study all patients admitted to the Emergency Department in the Institution between 01/2022 and 07/2023. The information about the recurrence of nose bleeding was searched on their medical file and by calling the patient to confirm ou get the information. Thus, several potentiel risk factors were studied : oral anticoagulants, sex, INR, anti-platelets drugs, diabetes, obesity, arterial hypertension, heart failure, hemoglobin at the admission, history of chronic rhinosinusitis, appointment with an ENT during the acute bleeding, sleep apnea, age, anatomic abnormality, recent surgery within 2 months, previous admission within 30 days in the emergency department, nasal trauma.

The relation between recurrence and those factors were studied at first individually and then all the significant ones were analyzed with a multivarious statistical test.

This study aim to provide a pronostic score of recurrence that can happen after the 3 fisrt weeks after the event. When a recurrence happens before 3 weeks, this was considered to be a non control of the bleeding episode.

This score will be then tested on our cohort to evaluate specificity and sensibility.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patient who is admitted at the emergency department between 01/2022 and 07/2023 for nose bleeding.
  • Age over 18 yo

Exclusion criteria

  • Opposition to be included
  • Patient who has not his willness to provide opposition to participate.opposition

Treatment and study plan

Primary outcomes

  1. Survival without bleeding

    Time frame: 1 year

    Measuring the delay between the first epistaxis and a recurrence.

Study contacts

Contact information is provided by the study sponsor or research team.

Ashley BAGUANT, Doctor

CONTACT

[email protected]

+33476764522

Sponsors and collaborators

Lead sponsor

University Hospital, Grenoble

Other

Registry information

Official study title

Facteurs De Risques De Récidive D'épistaxis Chez L'adulte

Acronym: FREA

Important dates

Study start
2024
Primary completion
2025
Study completion
2025
First posted
Oct 24, 2024
Registry last updated
Oct 24, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.